The General Directorate of Medicines, Supplies and Drugs (Digemid) granted the Conditional Sanitary Registration to Molnupiravir, drug developed by the company Merck Sharp & Dohme (MSD), for sale in the country with a prescription. It is a pill for the treatment against coronavirus.
WATCH THIS: These are the side effects that vaccines against COVID-19 can cause
Through a statement, the pharmaceutical company explained that Molnupiravir is an antiviral that inhibits the replication of SARS-CoV-2. In addition, it can be administered even to patients who are receiving other treatments because it has a low risk of interaction with other medications.
It should be noted that, the pill is prescribed to adults who are within the first five days from the onset of symptoms and who have at least one risk factor for developing severe disease.
HOW IS IT TAKEN AND HOW OFTEN?
Molnupiravir is taken as four 200-milligram capsules twice a day for five days with or without food to reduce the risk of the patient’s condition worsening.
For his part, the Medical Manager of MSD, Alberto La Rosa, specified that Molnupiravir is a drug that is characterized by its simplicity of use. “For patients, the treatment is simple, with a low risk of interaction with other drugs and without dietary requirements. The advantages for doctors are its prescription as a single prescription, without any additional supplements and with a favorable tolerability profile”.
IT MAY INTEREST YOU: WHO: “The COVID-19 pandemic is not over and neither are its economic consequences”
STUDIES
Recently multiple studies in vitro independent developed in the United States, Germany, Poland, Belgium, the Czech Republic and the Netherlands show that Molnupiravir has consistent antiviral activity against Omicronthe variant COVID-19 predominant that currently circulates in Peru and the world.
After demonstrating its efficacy against COVID-19, the drug has been approved by the drug regulatory agencies of the United Kingdom, the United States, Denmark, Japan, Mexico, Colombia, among others.
